This public procurement contract involves the ongoing supply of a medicinal product containing the active ingredient denosumab at a strength of 120MG, intended for oncology indications (ATC M05BX04). The specific product is denosumab in the form of a 120MG injection solution, packaged as 1X1ML. The
Tender closed on 5 Jun 2025. Awaiting award.
No single supplier dominates the field.
In healthcare medical, THOMAYER HOSPITAL has awarded 12 contracts to 12 suppliers.
+6 more suppliers
Across healthcare medical, the most active winners are URTICA SP Z O O, SALUS INTERNATIONAL SP Z O O, URTICA SP Z OO — the field to beat, or your route in as a partner.
This public procurement contract involves the ongoing supply of the medicinal product containing the active substance nirsevimab (ATC J06BD08). The specific products required include: - LL-nirsevimab, 50MG injection solution, packaged as 1x0.5ML + 2 syringes - LL-nirsevimab, 100MG injection solution
This public procurement contract involves the ongoing supply of a medicinal product containing the active substance nusinersen (ATC M09AX07). The specific product is LL-nusinersen, in the form of a 2MG injection solution packaged as 1X5ML. The total quantity required is 200 units. This contract is i
This public procurement contract involves the ongoing supply of the medication Sevoflurane (ATC N01AB08), which is a 100% liquid for inhalation. The required quantity is 4,800 units, each in a 250ml container. Additionally, the contract includes the free loan of compatible vaporizers that must work
This public procurement contract involves the delivery and complete implementation of software and hardware solutions for multi-factor authentication (MFA) and single sign-on (SSO). The contract also includes the provision of ongoing support, which will be covered by a separate service agreement. Th
A three-year funded fellowship helping healthcare professionals with PhDs return to clinical research after extended career breaks.
MMUH seeks a dermatology service provider to help meet increased demand for dermatological care through outsourced clinical services.
Market engagement opportunity to provide input on capillary blood sampling device requirements for HSCNI Trusts; questionnaire submissions due by 14th November 2026.
Hull City Council seeks to award a £187,500 Drug and Alcohol Treatment and Recovery services contract from November 2026 to March 2029 via direct award; providers must submit representations by 27 October 2026.
